This company listing is no longer active
Heritage Cannabis Holdings Résultats passés
Passé contrôle des critères 0/6
Heritage Cannabis Holdings's earnings have been declining at an average annual rate of -30.5%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually. Revenues have been growing at an average rate of 50.5% per year.
Informations clés
-30.5%
Taux de croissance des bénéfices
-5.5%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 23.1% |
| Taux de croissance des recettes | 50.5% |
| Rendement des fonds propres | -96.4% |
| Marge nette | -67.4% |
| Dernière mise à jour des bénéfices | 31 Oct 2023 |
Mises à jour récentes des performances passées
Recent updates
Positive Sentiment Still Eludes Heritage Cannabis Holdings Corp. (CSE:CANN) Following 50% Share Price Slump
Mar 27
Positive Sentiment Still Eludes Heritage Cannabis Holdings Corp. (CSE:CANN) Following 33% Share Price Slump
Feb 11Investors Continue Waiting On Sidelines For Heritage Cannabis Holdings Corp. (CSE:CANN)
Dec 18Heritage Cannabis Holdings (CSE:CANN) Has Debt But No Earnings; Should You Worry?
Sep 16Heritage Cannabis Holdings Corp. (CSE:CANN) Looks Inexpensive After Falling 33% But Perhaps Not Attractive Enough
Jul 22Is Heritage Cannabis Holdings (CSE:CANN) Using Too Much Debt?
Jun 15Heritage Cannabis Holdings (CSE:CANN) Is Carrying A Fair Bit Of Debt
Aug 11Is Heritage Cannabis Holdings (CSE:CANN) A Risky Investment?
Aug 24Can You Imagine How Elated Heritage Cannabis Holdings' (CSE:CANN) Shareholders Feel About Its 775% Share Price Gain?
Mar 03Is Heritage Cannabis Holdings (CSE:CANN) Weighed On By Its Debt Load?
Jan 07Ventilation des recettes et des dépenses
Comment Heritage Cannabis Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Oct 23 | 30 | -20 | 16 | 0 |
| 31 Jul 23 | 30 | -33 | 19 | 0 |
| 30 Apr 23 | 29 | -35 | 19 | 0 |
| 31 Jan 23 | 29 | -33 | 17 | 0 |
| 31 Oct 22 | 30 | -24 | 17 | 0 |
| 31 Jul 22 | 26 | -40 | 13 | 0 |
| 30 Apr 22 | 23 | -44 | 14 | 0 |
| 31 Jan 22 | 19 | -48 | 14 | 0 |
| 31 Oct 21 | 14 | -57 | 13 | 0 |
| 31 Jul 21 | 11 | -20 | 11 | 0 |
| 30 Apr 21 | 9 | -13 | 8 | 0 |
| 31 Jan 21 | 6 | -10 | 7 | 0 |
| 31 Oct 20 | 8 | -9 | 6 | 0 |
| 31 Jul 20 | 10 | -4 | 8 | 0 |
| 30 Apr 20 | 8 | -8 | 10 | 0 |
| 31 Jan 20 | 7 | -11 | 11 | 0 |
| 31 Oct 19 | 4 | -13 | 12 | 0 |
| 31 Jul 19 | 0 | -14 | 11 | 0 |
| 30 Apr 19 | 0 | -11 | 9 | 0 |
| 31 Jan 19 | 0 | -8 | 8 | 0 |
| 31 Oct 18 | 0 | -6 | 7 | 0 |
| 31 Jul 18 | 0 | -4 | 6 | 0 |
| 30 Apr 18 | 0 | -3 | 5 | 0 |
| 31 Jan 18 | 0 | -2 | 4 | 0 |
| 31 Oct 17 | 0 | 0 | 2 | 0 |
| 31 Jul 17 | 0 | -2 | 1 | 0 |
| 30 Apr 17 | 0 | -2 | 2 | 0 |
| 31 Jan 17 | 0 | -1 | 1 | 0 |
| 31 Oct 16 | 0 | -1 | 1 | 0 |
| 31 Jul 16 | 0 | -1 | 1 | 0 |
| 30 Apr 16 | 0 | -1 | 1 | 0 |
| 31 Jan 16 | 0 | -1 | 1 | 0 |
| 31 Oct 15 | 0 | -1 | 1 | 0 |
| 31 Jul 15 | 0 | -2 | 1 | 0 |
| 30 Apr 15 | 0 | -2 | 1 | 0 |
| 31 Jan 15 | 0 | -2 | 1 | 0 |
| 31 Oct 14 | 0 | -2 | 1 | 0 |
| 31 Jul 14 | 0 | 0 | 0 | 0 |
| 30 Apr 14 | 0 | 0 | 0 | 0 |
| 31 Jan 14 | 0 | -1 | 0 | 0 |
| 31 Oct 13 | 0 | 0 | 0 | 0 |
Des revenus de qualité: CANN is currently unprofitable.
Augmentation de la marge bénéficiaire: CANN is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CANN is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.
Accélération de la croissance: Unable to compare CANN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CANN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Rendement des fonds propres
ROE élevé: CANN has a negative Return on Equity (-96.37%), as it is currently unprofitable.